Oral contraceptive use and risk of melanoma in premenopausal women

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 918-923

  Feskanich, D ^a   Hunter, D J ^a,b,c   Willett, W C ^a,b   Spiegelman, D ^b   Stampfer, M J ^a,b   Speizer, F E ^a,b   Colditz, G A ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

Melanoma; Oestrogen; Oral contraceptives; Premenopausal

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HAIR; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PARITY; PREMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SKIN MANIFESTATION; SUN EXPOSURE; SUNBURN; TIME;

ADULT; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HAIR COLOR; HUMANS; INCIDENCE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREMENOPAUSE; RISK FACTORS; SUNBURN;

EID: 0032748245     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690787     Document Type: Article

References (38)

1. Armstrong BK and English DR (1996) Cutaneous malignant melanoma. In: Cancer Epidemiology and Prevention, 2nd edn. Schottenfeld D and Fraumeni JF (ed), pp. 1281-1312. Oxford University Press: New York
2. Bain C, Hennekens CH. Speizer FE, Rosner B, Willett W and Belanger C (1982) Oral contraceptive use and malignant melanoma. J Natl Cancer Inst 68: 537-539
3. Beral V, Ramcharan S and Faris R (1977) Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36: 804-809
4. Beral V, Evans S, Shaw H and Milton G (1984) Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 50: 681-685
5. Chaudhuri PK, Walker MJ, Briele HA, Beattie CW and Das Gupta TK (1980) Incidence of estrogen receptors in benign nevi and human malignant melanoma. JAMA 244: 791-793
6. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi BG, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC and Bacchi M (1992) Treatment of metastatic malignant melonoma with decarbazine plus tamoxifen. N Engl J Med 327: 517-523
7. Colditz GA, Manson JE and Hankinson SE (1990) The Nurses' Health Study; 20-year contribution to the understanding of health among women. J Women Health 6: 49-62
8. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727
9. D'Agostino RB, Lee MLT, Belanger AJ, Cupples LA, Anderson K and Kannel WB (1990) Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 9: 1501-1515
10. DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7: 177-188
11. Fisher RI, Heifeld JP and Lippman ME (1976) Oestrogen receptors in human malignant melanoma. Lancet 2: 337-339
12. Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ and Spinelli JJ (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br J Cancer 52: 901-907
13. Hannaford PC, Villard-Mackintosh L, Vessey MP and Kay CR (1991) Oral contraceptives and malignant melanoma. Br J Cancer 63: 430-433
14. Helmrich SP, Rosenberg L, Kautinan DW, Miller DR, Schottenfeld D, Stolley PD and Shapiro S (1984) Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst 72: 617-620
15. Holly EA, Weiss NS and Liff JM (1983) Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 70: 827-831
16. Holly EA, Cress RD and Ahn DK (1995) Cutaneous melanoma in women: reproductive factors and oral contraceptive use. Am J Epidemiol 141: 943-950
17. Holman CDJ, Armstrong BK and Heenan PJ (1984) Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 50: 673-680
18. Holman CDJ, Armstrong BK and Heenan PJ (1986) Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 76: 403-414
19. Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ. Speizer FE and Willett WC (1997) Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 56: 373-378
20. Jelinck JE (1970) Cutaneous side effects of oral contraceptive. Arch Dermatol 101: 181-186
21. Le MG, Cabanes PA, Desvignes V, Chanteau MF, Mlika N and Avril MF (1992) Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 3: 199-205
22. Liu T and Soong S J (1996) Epidemiology of malignant melanoma. Surgical Clinics N Amer 76: 1205-1221
23. MacKie RM, Freudenberger T and Aitchison TC (1980) Personal risk-factor chart for cutaneous melanoma. Lancet 2: 487-490
24. McCarty KS Jr, Wortman J, Stowers S, Lubahn DB, McCarty KS Sr and Seigler HF (1980) Sex steroid receptor analysis in human melanoma. Cancer 46: 1463-1470
25. McClay EF, Mastrangelo MJ, Berd D and Bellet RE (1992) Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553-556
26. McClay EF, Albright KD, Jones JA, Christian RD and Howell SB (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571-1576
27. Mirimanoff RO, Wagenknecht L and Hunziger N (1981) Long-term complete remission of malignant melanoma with tamoxifen. Lancet 1: 1368-1369
28. Nesbit RA, Woods RL, Tattersall MH, Tox RM, Forbes JF, MacKay IR and Goodyear M (1979) Tamoxifen in malignant melanoma [letter]. N Engl J Med 301: 1241-1242
29. Osterlind A, Tucker MA, Stone BJ and Jensen OM (1988a) The Danish case control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 42: 319-324
30. Osterlind A, Tucker MA, Stone RJ and Jensen OM (1988b) The Danish case-control study of cutaneous malignant melanoma: hormonal and reproductive factors in women. Int J Cancer 42: 821-824
31. Palmer JR, Rosenberg L, Stron BL, Harlap S, Zauber AG, Warehauer ME and Shapiro S (1992) Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 3: 547-554
32. Ramcharan S, Pellegrin FA, Ray R and Hsu JP (1981) The Walnut Creek Contraceptive Drug Study, Vol. III. NIH Publication No 81 564. US Government Printing Office: Washington, DC
33. Snell RS and Bischitz PG (1960) The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol 35: 73-82
34. Telhaug R, Klepp O and Bormer O (1982) Phase II study of tamoxifen in patients with metastatic malignant melanoma. Cancer Treat Rep 66: 1437
35. Wagstaff J, Thatcher N, Rankin E and Crowther D (1982) Tamoxifen in the treatment of metastatic malignant melanoma. Cancer Treat Rep 66: 1771
36. Weinstock MA, Colditz GA, Willett WC, Stampfer MC, Bronstein BR, Mihm MC and Speizer FE (1989) Non-familial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 84: 199-204
37. Westerdahl J, Olsson H, Masback A, Ingvar C and Johsson N (1996) Risk of malignant melanoma in relation to drug intake, alcohol, smoking, and hormonal factors. Br J Cancer 73: 1126-1131
38. Zanetti R, Franceschi S, Rosso S, Bidoli E and Colonna S (1990) Cutaneous malignant melanoma in females: the role ot hormonal and reproductive factors. Int J Epidemiol 19: 522-526